Evidence map›Paper›PMID 24704829›Full record

ArticleOncogene2015

Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity.

N Li, K Lee, Y Xi, B Zhu, B D Gary, V Ramírez-Alcántara, E Gurpinar, J C Canzoneri, A Fajardo, S Sigler and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase.International journal of molecular sciences · 2022
    Review
  19. Review
  20. Suppression of Colon Tumorigenesis in MutantCancer prevention research (Philadelphia, Pa.) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

N LiDepartment of Biochemistry and Molecular Genetics, The University of Alabama at Birmingham, Birmingham, AL, USA.
K LeeDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
Y XiDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
B ZhuDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
B D GaryDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
V Ramírez-AlcántaraDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
E GurpinarDepartment of Pharmacology and Toxicology, The University of Alabama at Birmingham, Birmingham, AL, USA.
J C CanzoneriDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
A FajardoDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
S SiglerDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
J T PiazzaDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
X ChenDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
J AndrewsDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
M ThomasDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
W LuDrug Discovery Division, Southern Research Institute, Birmingham, AL, USA.
Y LiDrug Discovery Division, Southern Research Institute, Birmingham, AL, USA.
D J LaanSchool of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
M P MoyerINCELL Corporation LLC, San Antonio, TX, USA.
S RussoDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
B T EberhardtDepartment of Chemistry, University of South Alabama, Mobile, AL, USA.
L YetDepartment of Chemistry, University of South Alabama, Mobile, AL, USA.
A B KeetonDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
W E GrizzleDepartment of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.
G A PiazzaDepartment of Oncologic Sciences and Pharmacology, Drug Discovery Research Center, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
University of Alabama at Birmingham · USSouthern Research Institute · USUniversity of South Alabama · USIncell Corporation (United States) · US

Funding

Pulmonary Hypertension Breakthrough InitiativeR24HL123767 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI ALDRED, MICHEALA A, ERZURUM, SERPIL C. · 2014 to 2017
$10.1M
Selective anti-cancer activity of sulindac derivatives on KRAS mutant colon tumor cells by inducing ROSR01CA131378 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2008 to 2019
$5.2M
Airway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2M
Development of a novel sulindac amide for colorectal cancer chemopreventionR01CA148817 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2010 to 2015
$2.4M
Phosphodiesterase 5: A Novel Target and Inhibitor for Breast Cancer ChemopreventionR01CA155638 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI PIAZZA, GARY A · 2012 to 2017
$2.3M
NCI NIH HHS 1R01CA131378NCI NIH HHS 1R01CA148817NCI NIH HHS 1R01CA155638NCI NIH HHS R01 CA131378NCI NIH HHS R01 CA148817NCI NIH HHS R01 CA155638NHLBI NIH HHS R24 HL123767NHLBI NIH HHS U10 HL109250
6 · The paper itself

Abstract

The cyclic nucleotide phosphodiesterase 10A (PDE10) has been mostly studied as a therapeutic target for certain psychiatric and neurological conditions, although a potential role in tumorigenesis has not been reported. Here we show that PDE10 is elevated in human colon tumor cell lines compared with normal colonocytes, as well as in colon tumors from human clinical specimens and intestinal tumors from Apc(Min/+) mice compared with normal intestinal mucosa, respectively. An isozyme and tumor-selective role of PDE10 were evident by the ability of small-molecule inhibitors and small interfering RNA knockdown to suppress colon tumor cell growth with reduced sensitivity of normal colonocytes. Stable knockdown of PDE10 by short hairpin RNA also inhibits colony formation and increases doubling time of colon tumor cells. PDE10 inhibition selectively activates cGMP/cGMP-dependent protein kinase signaling to suppress β-catenin levels and T-cell factor (TCF) transcriptional activity in colon tumor cells. Conversely, ectopic expression of PDE10 in normal and precancerous colonocytes increases proliferation and activates TCF transcriptional activity. These observations suggest a novel role of PDE10 in colon tumorigenesis and that inhibitors may be useful for the treatment or prevention of colorectal cancer.

Indexed as

beta CateninCell Line, TumorCell ProliferationColonic NeoplasmsGene Expression Regulation, NeoplasticGene Knockdown TechniquesHCT116 CellsHEK293 CellsHT29 CellsHumansPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesRNA, Small InterferingSignal TransductionTCF Transcription FactorsTranscription, Geneticbeta CateninCTNNB1 protein, humanPDE10A protein, humanPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesRNA, Small InterferingTCF Transcription Factors

Identifiers

PMID24704829
PMCPMC4212019
OpenAlexW2037521370

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.